Breaking News

Morgan Stanley to Pay $275 Million to Settle Subprime SEC Charges

OptiMedica Granted Fundamental Patent on Laser Cataract Surgery by U.S. Patent & Trademark Office

  OptiMedica Granted Fundamental Patent on Laser Cataract Surgery by U.S.
  Patent & Trademark Office

Business Wire

SUNNYVALE, Calif. -- February 25, 2013

OptiMedica Corp. has announced that the U.S. Patent & Trademark Office (USPTO)
has granted the company a patent relating to the fundamental technology
underlying laser cataract surgery. The OptiMedica patent, which will issue on
March 12, 2013 as U.S. patent no. 8394084, contains broad claims and describes
a 3D image-based femtosecond laser system for performing anterior capsulotomy
and lens fragmentation during the cataract procedure.

“We are gratified to see the USPTO recognize the novelty of our invention and
its practical realization in OptiMedica’s Catalys^® Precision Laser System,”
said Dr. Mark Blumenkranz, Professor and Chairman of the Department of
Ophthalmology at Stanford University, OptiMedica board member, recognized
authority in ophthalmology and one of the inventors of the technology. “Laser
cataract surgery is an exciting new breakthrough in ophthalmology, and it has
been an honor to be at the forefront of its advance.”

Co-invented by Dr. Daniel Palanker of the Departments of Physics and
Ophthalmology at Stanford University, OptiMedica’s Catalys has been shown in
numerous clinical studies to perform the laser cataract procedure with
precision and accuracy that is unparalleled in the industry.^1-3 In addition,
laser lens fragmentation with Catalys has been shown to dramatically reduce or
eliminate the need for ultrasound energy to break up and remove the

“The patent issuance is a terrific milestone affirming OptiMedica’s pioneering
position in the new global market for laser cataract surgery,” said Mark J.
Forchette, president and chief executive officer of OptiMedica. “This is truly
breakthrough technology, and it is very satisfying to see the foresight and
innovative leadership of its inventors recognized by the USPTO.”

The U.S. patent supporting Catalys is one in a series that OptiMedica has
filed for the system and its underlying technology worldwide. These include
five issued international patents as well as more than 30 pending patents in
the U.S. and more than 25 pending international patents.

Since its international launch in November 2011 and U.S. launch in February
2012, Catalys has been named one of the top medical technology products in the
world. The system has won the prestigious R&D 100 award from R&D Magazine and
was also a finalist in the 2012 Medical Design Excellence Awards.

About Catalys

Catalys is a precision laser cataract surgery platform that delivers gentle,
highly customized procedures with best-in-class accuracy and performance.^1-3
Catalys combines a femtosecond laser, integrated 3D Optical Coherence
Tomography (OCT) imaging, OptiMedica’s breakthrough pattern scanning
technology and a number of other unique features that distinguish it in the
field. These include a Liquid Optics™ Interface that ensures stable
system-patient attachment and optimizes the optical path to the patient’s eye;
a proprietary Integral Guidance™ mapping system that ensures the femtosecond
laser pulses are delivered safely and precisely to the intended location; and,
an elegant, easy-to-use graphical user interface that simplifies the treatment
planning process and minimizes the time the patient is under the laser.
Surgeons have reported exceptional results with Catalys, including complete
capsulotomies in 99 to 100 percent of procedures, elimination of ultrasound
energy during lens disassembly and removal, and exceptionally precise corneal

About OptiMedica

Founded in 2004 and headquartered in Sunnyvale, Calif., OptiMedica Corp. is
Silicon Valley-based global ophthalmic device company dedicated to developing
performance-driven technologies that improve patient outcomes. Exclusively
focused in the cataract therapeutic area, the company has developed the
Catalys Precision Laser System to transform existing standards of care in
cataract surgery.

OptiMedica’s legacy of innovation in ophthalmology also includes the
development and commercialization of the PASCAL^® Method of retinal
photocoagulation, which was acquired by Topcon Corp. in August 2010. The
company is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG
Ventures, BlackRock Private Equity Partners and Bio*One Capital. For more
information, please visit


^1 Palanker DV, et al. “Femtosecond laser-assisted cataract surgery with
integrated optical coherence tomography.” Sci Transl Med. 2010 Nov
^2 Friedman NJ, et al. “Femtosecond laser capsulotomy.” J Cataract Refract
Surg. 2011 Jul;37(7):1189-98.
^3 Culbertson, B. “Optimization of corneal incision parameters with a
femtosecond laser for cataract surgery.” XXX Congress of the ESCRS, Sept.
^4 Conrad-Hengerer I, Hengerer FH, Schultz T, Dick HB. “Effect of femtosecond
laser fragmentation on effective phacoemulsification time in cataract
surgery.” J Refract Surg. 2012 Dec;28(12):879-83.
^5 Conrad-Hengerer I, Hengerer FH, Schultz T, Dick HB. “Effect of femtosecond
laser fragmentation of the nucleus with different softening grid sizes on
effective phaco time in cataract surgery.” J Cataract Refract Surg. 2012 Nov;
38(11): 1888-94.
^6Abell RG, Kerr NM, Vote BJ. “Catalys femtosecond laser-assisted cataract
surgery compared to conventional cataract surgery.” Clin Experiment
Ophthalmol. 2012 in press.


Nobles Global Communications
Laura Nobles